Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer
1Memorial Sloan-Kettering Cancer Center, New York, NY 10065-6007, USA. makir@mskcc.org
Abstract:
Insulin-like growth factors were discovered more than 50 years ago as mediators of growth hormone that effect growth and differentiation of bone and skeletal muscle. Interest of the role of insulin-like growth factors in cancer reached a peak in the 1990s, and then waned until the availability in the past 5 years of monoclonal antibodies and small molecules that block the insulin-like growth factor 1 receptor. In this article, we review the history of insulin-like growth factors and their role in growth, development, organism survival, and in cancer, both epithelial cancers and sarcomas. Recent developments regarding phase I to II clinical trials of such agents are discussed, as well as potential studies to consider in the future, given the lack of efficacy of one such monoclonal antibody in combination with cytotoxic chemotherapy in a first-line study in metastatic non-small-cell lung adenocarcinoma. Greater success with these agents clinically is expected when combining the agents with inhibitors of other cell signaling pathways in which cross-resistance has been observed.
Insights
Insulin-like growth factors (IGFs) are key to growth and development. New therapies targeting IGF-1 receptor show promise for cancer treatment, especially when combined with other pathway inhibitors.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Insulin-like growth factors (IGFs) have long been recognized for their roles in growth and differentiation.
- Interest in IGFs' role in cancer resurged with the development of targeted therapies.
Purpose of the Study:
- To review the history and multifaceted roles of IGFs in biological processes and cancer.
- To discuss recent clinical trials and future directions for IGF-targeting agents in oncology.
Main Methods:
- Literature review of IGFs' historical significance and biological functions.
- Analysis of recent Phase I-II clinical trial data for IGF-1 receptor inhibitors.
- Exploration of combination therapy strategies for enhanced efficacy.
Main Results:
- IGFs are crucial for growth, development, and survival, and are implicated in various cancers.
- Early clinical trials of IGF-1 receptor inhibitors have yielded mixed results, with some showing limited efficacy.
- Combination therapies targeting IGF signaling alongside other pathways show potential for improved outcomes.
Conclusions:
- IGFs play a significant role in both normal physiology and oncogenesis.
- Targeting the IGF-1 receptor presents a therapeutic avenue for cancer, but requires optimized strategies.
- Future clinical success may depend on combining IGF inhibitors with agents targeting cross-resistant signaling pathways.
Related Concept Videos
Mitogens and the Cell Cycle
Mitogens and the Cell Cycle
Cells Coordinate Growth and Proliferation
Cells Coordinate Growth and Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

